Johnson & Johnson’s Janssen Biotech has licensed global rights to certain prostate cancer immunotherapies developed by Aduro BioTech based on its LADD platform, which uses live-attenuated double-deleted Listeria monocytogenes strains. Separately, Janssen has also licensed exclusive global rights to Aduro’s GVAX vaccine technology for prostate cancer. GVAX and LADD have been shown to be synergistic in preclinical models. Janssen already markets Zytiga® (abiraterone acetate) for castration-resistant prostate cancer and gained Phase III ARN-509 with its acquisition of Aragon Pharmaceuticals.